Acadia Pharmaceuticals Inc. (ACAD)

[TruckingAngler]

Sorry 3 weeks was too long to wait...?
I also bought on 3/09, but if you only buy a stock "because it went down" - you likely will have more losses than gains.
ACAD will be back over $40. It may not be next week. It may not be next Month.
I added today, and expect better news to follow... Later...
GLTA

[jerseyboy]

Thank you. I used to love biopharmas, but the FDA's new hard guy position on this and other biopharmas has made them not worth the risk of owning, in my opinion. It's too bad, because it will make raising capital more expensive for the whole industry, especially fledgling drug companies, and will hinder the development of drugs that could have massive benefit for society. For example, I would love to put some money into ALRN, as they have the potential to develop a drug that's similar or superior in efficacy to that for which GTHX just got approval, but I wouldn't touch it now because of the risk of their running afoul of the FDA in the approval process.

I think you're going to be O.K. here in the long run, but I sold this and put the money into WKHS because I don't have the time to let this money sit here dead for an indeterminate period of time when WKHS has a product that can transform the face of end-mile transportation, and they don't have to wait for FDA approval to move forward.

[gi197845]

Jerseyboy, I actually think you have some good points. I had to average down, because I was already underwater and will hold until bankruptcy or a break even.

[jerseyboy]

Yeah, an opportunity to get my ass kicked even further. I bought this POS when it got killed the first time and thought it couldn't fall any further. Guess what - I was wrong! I sold out of this mess this morning at a loss and I'll never touch another biopharma again - they're not worth the nebulous risk/reward profile, particularly now that the FDA has turned into assholes.

[LasNubes]

Agreed. Nothing wrong with the pipeline either !!

[AlphaStockNews]

$ACAD is falling hard after announcing it has received a CRL. These declines may be a massive opportunity. https://cnafinance.com/acad-stock-acadia-declines-are-an-opportunity/

[jerseyboy]

I haven't gotten into crypto at all. I don't mind investing in things I don't fully understand, but I don't even understand the value proposition of crypto. I do understand the value proposition of NNDM, which I will be buying tomorrow morning. Listening to their Q4 conference call was extremely exciting for me today. It's not for everyone, but for those who can see the future, the value is absolutely there.

[gi197845]

Well ya, if that's your entry price it sounds good. Some have averaged down. It's a risk either way. I am way under water now on ACAD, so much so, that I'm not selling and have averaged down, still worried as hell, but I am hopeful as well. Obviously, I don't like my investment being tied up for long term and being dead money. You are smarter than me! I should have averaged down last year when it dropped to $17, based on CNN's bashing.
Are you into crypto at all?

[jerseyboy]

I'm hoping so - that's why I bought in at $23.79 - the price just intuitively seemed too low.

[gi197845]

Ok, well let's hope there is some positive news. Did you see the recent Barrons article about the FDA? Fewer mergers, price fixing, more rejections, CRLs and delays...

[LasNubes]

ACAD will shoot up with any positive PR !

The bottom is baked in here especially with the pipeline assets, IMHO.

[gi197845]

The FDA sucks.

[jerseyboy]

They certainly stand to lose a lot more than I do if the FDA approval isn't obtained! I think I'll hold and see what happens, as my $23.79 position is still making money.

[gi197845]

Baker Brothers Info:
Look at the 1yr chart of all their holdings.
https://whalewisdom.com/filer/baker-bros-advisors-llc#tabholdings_tab_link

[gi197845]

I still hold ACAD and increased my position @ 23 and will increase even down. As a result, my average PPS went lower. Obviously, I'm taking a big chance here and of course I want the DRP approval ASAP. The FDA really messed us up and it doesn't look good.

[blast1977]

Soo what’s next ? Good entry point at this level ?

[jerseyboy]

It's hard for me to believe that people are stupid enough to think that this company is worth 52% of what it was yesterday just because the FDA apparently has some issues with the application. I bought in today at $23.79 and am very happy to have gotten such a tremendous discount on the company's valuation.

[north40000]

[blast1977]

Even if it goes lower it’s still a nice 50% discount for the long term.

[LasNubes]

I agree
I had this a long time ago and had a great run with it years ago.

Some of the other pipeline drugs look extremely promising including their purchase of CerSci and their non-opioid pain drug !

[harry crumb]

Hhhmmmmmm...., unreal here!

[blast1977]

Agreed without the FDA on the medication that is not good

[girlfriend]

Good Luck!

I am waiting for lower....large short position here but you never know what you will get with ACAD.

I remember holding ACAD from $17 to $19 a share for a LONG time then one day....POW!

I have bids in below $20...if she gets there great.....if not no biggie.

Hope ACAD resolves the issue.

[LasNubes]

Just bought in pre-market at $25.89

ACAD will sit down with the FDA and get it resolved.

This, IMO, is a market over reaction at this point and makes a great buying opportunity!

[Docstemcell2020]

WOW!

[Bostonboy70]

Looks like DRP is in high risk for April review.

[blast1977]

Seems to never be able to pass $54-55

[gi197845]

LOL, ok.

[Bostonboy70]

Anyone selling into DRP? Thinking $65is a good out?

[gi197845]

Uh Oh...Oppsie, ACAD being sued, ACAD is now F'd with a capital F.
Shuman Glenn
1:31 PM ET 1/11/21 | BusinessWire
DENVER--(BUSINESS WIRE)--January 11, 2021--

Shuman Glenn & Stecker announces that it is investigating potential shareholder claims against certain officers and directors of Acadia Pharmaceuticals, Inc. ("Acadia" or the "Company") (NYSE: ACAD). Acadia is a biopharmaceutical company focusing on the development and commercialization of medicines to address central nervous system disorders. The Company's lead drug, NUPLAZID, was approved in 2016 by the U.S. Food and Drug Administration ("FDA") for treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

The Firm's investigation relates to allegations in a securities fraud class action lawsuit against Acadia and certain of its senior officers in the U.S. District Court for the Southern District of California. The lawsuit alleges that the defendants failed to publicly disclose material facts, including: (i) adverse events, safety concerns, and mounting reports of deaths related to NUPLAZID post-commercialization, which raised the risk that the FDA would reconsider its approval of NUPLAZID and/or that industry watchdogs would warn against prescribing NUPLAZID; (ii) that Acadia undertook a campaign to pay off physicians to prescribe NUPLAZID; and (iii) that Acadia's improper business practices exposed the Company to potential regulatory scrutiny. In a June 1, 2020 ruling denying in part the motion to dismiss the lawsuit, the federal judge determined that it had been sufficiently alleged that the defendants did not properly disclose the high mortality rate during testing for NUPLAZID or the payments of kickbacks to doctors who prescribed NUPLAZID.

On April 9, 2018, following a CNN report about mounting deaths associated with NUPLAZID, Acadia's stock price fell by over 23% to close at $16.50 per share. After CNN subsequently reported on April 25, 2018 that the FDA was re-examining the safety of NUPLAZID, Acadia's stock price fell again, by nearly 22% to close at $15.20 per share.

If you currently own Acadia common stock and are interested in discussing your rights, or have information relating to this investigation, please contact Kip Shuman toll free at [phone] or email Mr. Shuman at [e-mail].

Shuman Glenn & Stecker represents investors throughout the nation, concentrating its practice in stockholder litigation.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210111005918/en/

CONTACT: SHUMAN GLENN & STECKER

Kip B. Shuman, Esq.

100 Pine Street, Suite 1250

San Francisco, CA 94111

Tel: [phone]

Fax: [phone]

Email: [e-mail]

Web: www.shumanlawfirm.com

SOURCE: Shuman Glenn & Stecker
Copyright Business Wire 2021


> Dow Jones Newswires

January 11, 2021 13:31 ET (18:31 GMT)

[harry crumb]

Strong as ever! $$$

[gi197845]

If it does go down that far or more, it would probably be good to buy more. Next year in Q1, ACAD could receive approval, for other indications, resulting in more sales, larger market cap, better/increased share price.

[blast1977]

So what’s next ? $49 then $44 ? Any thoughts about the decline ?

[gi197845]

https://finance.yahoo.com/news/acadia-pharmaceuticals-inc-nasdaq-acad-042114305.html

[gi197845]

Thanks Harry, I was just worried that lower drug prices means lowered pharma profits, means lowered stock price, means lowered earnings for pharma investors. It's almost as if a cap is being put on pharma's potential earnings.

I know low drug prices are good for the patients/consumers.

I don't know all the details of the plan, but if it's truly going to lower drug prices, then somehow, also lower the cost of drug trials and dealing with the FDA.

[harry crumb]

Drugs that are needed will still be sold, cheaper drugs could mean more drugs sold, so to be honest i think nothing will change with longterm results.

[gi197845]

President Trump is making major changes to the costs of prescription drugs. I'm not going to be able to put all the details in this post, but it should lower prices by 50%. I'm not here to debate who is the true president or not. Even if Trump is out of office, this sounds like it's happening. I also understand that lower drug prices is good for the consumer. My question to all of you is, how will this effect the stock price of ACAD?

[harry crumb]

Go acad! Still own a bunch yet here$$$$

[whytestocks]

News; $ACAD Acadia Pharmaceuticals to Present New Scientific Data on Pimavanserin in Neurodegenerative Diseases at the 13th Clinical Trials on Alzheimer's Disease (CTAD) Conference

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that scientific presentations highlighting new analyses of pimavanserin clinical study data in dementia-related psychosis and neurodegenerative diseases will be shared at the 13 th Clinical Trials on Alzheimer's Disease Conf...

Got this from ACAD - Acadia Pharmaceuticals to Present New Scientific Data on Pimavanserin in Neurodegenerative Diseases at the 13th Clinical Trials on Alzheimer's Disease (CTAD) Conference

[gi197845]

Acadia Pharmaceuticals Appoints Elizabeth Garofalo, M.D. to Board of Directors
9:00 AM ET 10/1/20 | BusinessWire


SAN DIEGO--(BUSINESS WIRE)--October 01, 2020--

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Elizabeth (Betsy) Garofalo, M.D. to its Board of Directors. Dr. Garofalo is a biopharma executive with more than 25 years of experience in global clinical development and regulatory affairs.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201001005364/en/

Dr. Elizabeth Garofalo (Photo: Business Wire)

"Dr. Garofalo is a highly-regarded business leader and innovator with invaluable clinical development experience," said Stephen R. Biggar, M.D., Ph.D., Chairman of Acadia's Board of Directors. "We are excited to welcome her to the Board of Directors and look forward to leveraging her significant CNS research and development expertise, particularly as the company advances its innovative late stage and growing early stage pipeline."

"I look forward to working with the talented Acadia management team as they continue to seek breakthroughs in the field of CNS, pioneering new research and developing innovative new therapies to address unmet needs, " said Dr. Garofalo.

Since 2016, Dr. Garofalo has served as the Principal for EAG Pharma Consulting LLC. Prior to that, Dr. Garofalo served in numerous leadership roles including as the Global Head of Clinical Development and member of the Novartis Global Development Leadership Team, Chair of the Novartis Portfolio Stewardship Board, Co-Head of the Novartis Neuroscience Franchise, Head of the Neuroscience Therapy Area at Astellas, Ann Arbor Site Head of Worldwide Regulatory Affairs at Pfizer, and Ann Arbor Site Head of Neuroscience at Pfizer.

Dr. Garofalo currently serves on the board for the Institute for Advanced Clinical Trials in Children and is the Chair of the Business Advisory Board for the Epilepsy Foundation of America. She earned her M.D. from the Indiana University School of Medicine and completed fellowships in pediatric neurology and epilepsy at the University of Michigan Medical School.

About Acadia Pharmaceuticals

Acadia is trailblazing breakthroughs in neuroscience to elevate life through science. For more than 25 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialize the first and only approved therapy for hallucinations and delusions associated with Parkinson's disease psychosis. Our late-stage development efforts are focused on dementia-related psychosis, negative symptoms of schizophrenia and Rett syndrome, and in early-stage clinical research we are exploring novel approaches to pain management, and cognition and neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at www.acadia-pharm.com and follow us on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201001005364/en/

CONTACT: Media Contact:

Acadia Pharmaceuticals Inc.

Eric Endicott

[phone]

[e-mail]

Investor Contact:

Acadia Pharmaceuticals Inc.

Mark Johnson, CFA

[phone]

[e-mail]

SOURCE: Acadia Pharmaceuticals Inc.

Copyright Business Wire 2020

> Dow Jones Newswires

October 01, 2020 09:00 ET (13:00 GMT)

[gi197845]

In my opinion, yes Acadia is still a buy. I am underwater now anyway, so could be a good time to average down. Since Acadia bought the other pharma, I think it will take longer to become successful and for Acadia stock to mature, so short term gains and a buy out could be off the table now, but long term gains still look good and I'm long anyway.

Maybe the Baker Brothers or the Acadia CEO wants to try hanging onto a pharma and letting it mature for once, rather than doing the buy out thing, who knows?

[blast1977]

Still a Buy ?

[gi197845]

It's obvious to me that Acadia does not want to be bought out. They have a sales force and they bought CerSci Therapeutics. Of course I could be wrong, but we'll see over the next couple of years.

[gi197845]

Uh Oh, Crash! Thanks fake news.

[harry crumb]

Added to the tank here! $$$

[IamnotTylerDurden]

Report looked solid, buying the dip...

[blast1977]

Time to buy ?
What’s happening

[gi197845]

Thanks, I added a bunch of shares on the dip down to $44.

[IanFromSI]

I agree completely. In addition, all of the buy side analysts that I've seen have lowered their price targets but reiterated their ratings. An overwhelming majority still has ACAD at strong buy.

April 3rd will be a binary decision date. The FDA has already approved, reviewed and confirmed approval for psychosis tx.

MDD not reaching stat sig reaction is quite probably overdone. The medical caregivers have already seen how it has helped their Parkinson's pts. There was never going to be a Nuplazid rx for psychosis and a separate one for MDD. I.e. It was always going to be one or the other or none.

So even if MDD isn't added to the label for dementia related Psychosis, the doctors will still try it, especially if ACAD continues its 30 day free trial for new pts, and we'll see nearly the same total sales anyway.

Assuming ACAD gets the April 3rd approval, it may take the market a quarter or 2 to get a handle on the new sales rate.

JMHO,Ian

[IamnotTylerDurden]

Great time to accumulate, as we still await FDA approval for Nuplazid for the treatment of dementia-related psychosis.

"On July 20, 2020, ACADIA  announced that the U.S. Food and Drug Administration (FDA) has accepted for filing its supplemental New Drug Application (sNDA) for NUPLAZID® (pimavanserin) for the treatment of hallucinations and delusions associated with dementia-related psychosis (DRP).

The FDA has assigned a standard review with a PDUFA (Prescription Drug User Fee Act) action date of April 3, 2021. The FDA has also informed the Company that it has not identified any potential review issues at this point in their evaluation and at this time they are not planning to hold an Advisory Committee meeting."

I remember listening intently to the Advisory Committee meeting for Nuplazid before approval for Parkinson's use. Based on trial data and no plan for meeting, I feel like it has a great chance for approval for dementia use.

I work in long term care with residents with dementia and this new approval would be an immense help for the lives of those residents, family and caregivers.

All IMO.